Results 211 to 220 of about 245,125 (261)
Some of the next articles are maybe not open access.
Resistance to Anti-VEGF Agents
Current Pharmaceutical Design, 2004The number of anti-angiogenic agents developed for clinical use has risen greatly over the past decade. Currently, more than 80 are in trials ranging from phase I through to phase III studies and many more are in preclinical evaluation. Much hope was envisaged for these new agents to become the panacea of anti-tumoural treatment.
Ton, N. C. +1 more
openaire +2 more sources
Anti-VEGF and Retinal Dystrophies
Current Drug Targets, 2020The therapeutic approach based on anti-vascular endothelial growth factor (anti-VEGF) molecules can be used to treat two important complications of retinal dystrophies: choroidal neovascularization and macular edema. The macular involvement in retinal dystrophies can lead to further visual deterioration in patients at a young age and already affected
Battaglia Parodi Maurizio +2 more
openaire +3 more sources
Anti-VEGF therapy for glaucoma
Current Opinion in Ophthalmology, 2010The role of antivascular endothelial growth factor (anti-VEGF) agents in treating various ophthalmic diseases is currently being investigated. There have been many advances in the understanding of how anti-VEGF agents work and speculation on when to implement them clinically for neovascular glaucoma.
Michael B, Horsley, Malik Y, Kahook
openaire +2 more sources
2021
In the current management of ROP, anti-VEGF drugs have a very significant role. These drugs can be used in ROP in different clinical situations: as a primary treatment for posterior ROP, for progressing cases after they have been previously treated either with a laser or with an anti-VEGF drug, and as an adjunct in ROP-related vitreoretinal surgery ...
Andrés Kychenthal, Paola Dorta
openaire +1 more source
In the current management of ROP, anti-VEGF drugs have a very significant role. These drugs can be used in ROP in different clinical situations: as a primary treatment for posterior ROP, for progressing cases after they have been previously treated either with a laser or with an anti-VEGF drug, and as an adjunct in ROP-related vitreoretinal surgery ...
Andrés Kychenthal, Paola Dorta
openaire +1 more source
2010
The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability.
Bandello F. +6 more
openaire +2 more sources
The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability.
Bandello F. +6 more
openaire +2 more sources
Acta Ophthalmologica, 2014
AbstractThe diabetic macular edema (DME) related to visual loss, results mainly from changes in the affected blood‐retina barrier. VEGF, originally described as vascular permeability factor, is considered not only as a critical stimulus of retinal neovascularization but also as the primary inducer of increased vascular permeability involved in the ...
openaire +1 more source
AbstractThe diabetic macular edema (DME) related to visual loss, results mainly from changes in the affected blood‐retina barrier. VEGF, originally described as vascular permeability factor, is considered not only as a critical stimulus of retinal neovascularization but also as the primary inducer of increased vascular permeability involved in the ...
openaire +1 more source
Anti-VEGF and intraocular pressure
British Journal of Ophthalmology, 2011It is with great interest that I read the article by Good and associates1 on sustained elevation of intraocular pressure (IOP) after anti-vascular endothelial growth factor (VEGF) injections. Though several authors have observed raised IOP after intravitreal injections,2–6 this study assumes great importance since the authors have tried to identify ...
openaire +2 more sources
Therapeutic Anti-VEGF Antibodies
2008Vascular endothelial growth factor (VEGF-A) is a key cytokine in the development of normal blood vessels as well as the development of vessels in tumors and other tissues undergoing abnormal angiogenesis. Here, we review the molecular engineering of two humanized antibodies derived from a common mouse anti-VEGF antibody--bevacizumab, a full-length IgG1
S, Lien, H B, Lowman
openaire +2 more sources
Acta Ophthalmologica, 2012
AbstractPurpose To assess safety and efficacy of intraocular injections of anti‐VEGF in patients with diabetic macular edema (DME)Methods The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischemic diabetic maculopathy and complications after laser application.
openaire +1 more source
AbstractPurpose To assess safety and efficacy of intraocular injections of anti‐VEGF in patients with diabetic macular edema (DME)Methods The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischemic diabetic maculopathy and complications after laser application.
openaire +1 more source
Acta Ophthalmologica, 2014
AbstractVascular endothelial growth factor A (VEGF‐A) was initially discovered as an endothelial cell‐specific growth factor, and current evidence suggests that it also plays numerous roles outside the vasculature, perhaps most significantly in the nervous system.
openaire +1 more source
AbstractVascular endothelial growth factor A (VEGF‐A) was initially discovered as an endothelial cell‐specific growth factor, and current evidence suggests that it also plays numerous roles outside the vasculature, perhaps most significantly in the nervous system.
openaire +1 more source